|
SLRX | Salarius Pharmaceuticals, Inc. |
|
|
SLRX | Salarius Pharmaceuticals, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 1.44 |
| Leverage | 30.33% |
| Market Cap | $ 3.0m |
| PE | 0.00 |
| Dividend Yield | 14722222.06% |
| Profit | $ -5.0m |
| Margin | 0.00% |
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, is focused on developing epigenetics-based cancer treatments. The company is headquartered in Houston, Texas.